Tables, listings and figures in a clinical study report - quality or quantity?

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Ning Li, Yaohua Zhang, Naitee Ting
{"title":"Tables, listings and figures in a clinical study report - quality or quantity?","authors":"Ning Li, Yaohua Zhang, Naitee Ting","doi":"10.1080/10543406.2025.2575942","DOIUrl":null,"url":null,"abstract":"<p><p>In pharmaceutical industry, a prevalent yet problematic phenomenon is that piles of statistical tables, listings and figures (abbreviation TLFs) are prepared and included in a clinical trial study report (CSR). While some TLFs convey critical insights and others provide essential context to help reviewers understand the various properties of the drug, many other TLFs are redundant and serve no meaningful purpose. The overabundance of unnecessary TLFs in the CSR body or appendix can have several detrimental effects: it may confuse or mislead reviewers, obscure the key messages and waste valuable resources. This paper aims to shed light on this pervasive issue, highlight its potential adverse consequences and explore the underlying reasons. We will present two case examples to illustrate our points and offer practical solutions and recommendations. Finally, we will conclude this paper with a remark.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1574-1586"},"PeriodicalIF":1.3000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2575942","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In pharmaceutical industry, a prevalent yet problematic phenomenon is that piles of statistical tables, listings and figures (abbreviation TLFs) are prepared and included in a clinical trial study report (CSR). While some TLFs convey critical insights and others provide essential context to help reviewers understand the various properties of the drug, many other TLFs are redundant and serve no meaningful purpose. The overabundance of unnecessary TLFs in the CSR body or appendix can have several detrimental effects: it may confuse or mislead reviewers, obscure the key messages and waste valuable resources. This paper aims to shed light on this pervasive issue, highlight its potential adverse consequences and explore the underlying reasons. We will present two case examples to illustrate our points and offer practical solutions and recommendations. Finally, we will conclude this paper with a remark.

临床研究报告中的表格、清单和数据——质量还是数量?
在制药行业中,一个普遍存在但存在问题的现象是,一份临床试验研究报告(CSR)中准备了大量的统计表、清单和数据(简称tlf)。虽然一些tlf传达了关键的见解,而另一些提供了必要的背景,以帮助审稿人理解药物的各种特性,但许多其他tlf是多余的,没有任何有意义的目的。企业社会责任正文或附录中过多不必要的tlf可能会产生一些不利影响:它可能会混淆或误导审稿人,模糊关键信息并浪费宝贵的资源。本文旨在揭示这一普遍存在的问题,突出其潜在的不良后果,并探讨其根本原因。我们将通过两个案例来说明我们的观点,并提供切实可行的解决方案和建议。最后,我们将对本文进行总结。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书